Education
About Us
Working with TipRanks
Follow Us
NextCure Inc (NXTC)
NASDAQ:NXTC
NXTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.69 - $19.80
Previous CloseN/A
Volume33.57K
Average Volume (3M)221.47K
Market Cap
$12.94M
Enterprise Value-$16.89M
Total Cash (Recent Filing)$35.31M
Total Debt (Recent Filing)$4.67M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Oct 30, 2025EPS Estimate
-3.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.29
Shares Outstanding2,676,110
10 Day Avg. Volume27,659
30 Day Avg. Volume221,469
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-1.31
Enterprise Value/Revenue-5.15
Enterprise Value/Gross Profit48.83
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$17.50Price Target Upside239.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial Phase 1 SIM0505 clinical data show promise, with a partial response observed in a serous endometrial carcinoma patient at the lowest dose, supporting its high potency profile.
Clinical TrialsThe Phase 1 dose-escalation trial for LNCB74 in breast, ovarian, and endometrial cancer is progressing quickly, with no dose-limiting toxicities reported.
PartnershipsNextCure's focus on ADCs and its partnership with Simcere, who has several ADC programs in development, provides potential for addressing resistant tumors.
Bears Say
CompetitionThe B7-H4 ADC landscape remains competitive with several clinical stage players, posing a challenge for NextCure.
Competitive LandscapeThe CDH6 ADC development landscape is becoming increasingly competitive, with significant clinical-stage competitors setting the bar for efficacy.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $2.69 and its highest was $19.80 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $12.94M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Oct 30, 2025 which is in 75 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Aug 07, 2025. The company reported -$11.29 earnings per share for the quarter, missing the consensus estimate of -$4.615 by -$6.675.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -3.98.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 2,676,110 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$11.29 in its last earnings report, missing expectations of -$4.615. Following the earnings report the stock price went down -4.51%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
NextCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (239.81% Upside)
$17.50 (239.81% Upside)
Hedge Fund Trend
Decreased
By 837.0 Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.96%
12-Months-Change
Fundamentals
Return on Equity
-104.07%
Trailing 12-Months
Asset Growth
-53.51%
Trailing 12-Months
Company Description
NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NXTC Stock 12 Month Forecast
Average Price Target
$17.50
▲(239.81% Upside)
Technical Analysis
Minerva Neurosciences
―
MetaVia
―
Portage Biotech Inc
―
180 Life Sciences
―
Aptorum Group
―
Ownership Overview
―
Insiders
7.21% Mutual Funds
36.79% Other Institutional Investors
52.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---